Bajaj Healthcare FY26 Financial Results: Profit Halves Despite Revenue Growth, Dividend Recommended

Bajaj Healthcare Ltd. has announced its audited standalone financial results for the fiscal year ended March 31, 2026. The company reported a Total Income of ₹618.17 crore, an increase from ₹562.01 crore in the previous fiscal year (FY25). However, profitability declined sharply.

Key Financials

Profit After Tax (PAT) for FY26 dropped by approximately 50% to ₹21.31 crore, down from ₹42.93 crore in FY25. Profit Before Tax also fell significantly to ₹28.92 crore from ₹46.01 crore in the prior year.

Why Profitability Declined

The substantial profit drop despite revenue growth points to margin pressure. This suggests either rising costs for goods sold or pricing challenges in the market impacting profitability. For instance, regional instability previously led to an income reversal of ₹3,324.66 lakh due to customer timeline issues, affecting the company's growth trajectory.

Shareholder Returns and Audits

The Board of Directors recommended a final dividend of 30%, equivalent to ₹1.50 per share, pending shareholder approval at the upcoming Annual General Meeting. JCR & Co. LLP has been appointed as the new Internal Auditors, and V.J. Talati & Co. has been re-appointed as Cost Auditors for the fiscal year 2026-27.

Background and Strategic Moves

Bajaj Healthcare operates in the competitive pharmaceutical sector, producing Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceuticals. The proposed acquisition of Genrx Pharmaceuticals Private Limited is currently pending approval from the National Company Law Tribunal (NCLT). This acquisition is considered key to consolidating Genrx as a subsidiary and expanding Bajaj Healthcare's operational footprint.

Risks and Outlook

Investors will be watching the company's ability to manage costs and market pricing effectively. The acquisition of Genrx Pharmaceuticals also introduces uncertainty pending NCLT clearance. The recommended dividend indicates commitment to shareholders, but the profit decline raises questions about the sustainability of future payouts and earnings growth.

Peer Comparison

Bajaj Healthcare operates in the API and formulations segment. Its peers, such as Aarti Drugs, also manufacture APIs and formulations and face similar market dynamics. Laurus Labs, another competitor in APIs and formulations, has also navigated sector-wide margin pressures and execution challenges.

Detailed Metrics

• Standalone Revenue from operations grew to ₹61103.14 lakh in FY26 from ₹54260.24 lakh in FY25.
• Standalone Profit After Tax declined to ₹2131.04 lakh in FY26 from ₹4292.88 lakh in FY25.
• Standalone Profit Before Tax decreased to ₹2892.30 lakh in FY26 from ₹4601.77 lakh in FY25.

What to Track Next

Key developments to monitor include the outcome of the Annual General Meeting regarding the final dividend, progress on the NCLT approval for the Genrx Pharmaceuticals acquisition, and management's commentary on margin compression and future outlook. Any updates on resolving regional instability issues impacting customer commitments will also be important.